June 13, 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Stace Wills to the board of directors. Mr. Wills is a resident Canadian and his appointment was effective June 12, 2013.
Commenting on the appointment, Mario Gobbo, Chairman of the Board of Helix, said, “Mr. Wills has over 20 years of experience in the life sciences, biotech and technology sectors and I look forward to the insights he will bring to our board and to working with him as Helix pursues its product development initiatives.”
Helix also announced that Andrew J. MacDougall, who had agreed to serve on the board of directors on an interim basis pending the appointment of a resident Canadian director to satisfy the statutory requirement for resident Canadians to comprise at least 25% of Helix’s board of directors, voluntarily resigned as a director following the appointment of Mr. Wills. Mr. Gobbo commented, “Mr. MacDougall’s interim service on the board has provided us with time to complete our director recruitment process. We thank him for his contributions as a director and look forward to his continued service as counsel to the company.”
Following the appointment of Mr. Wills and the resignation of Mr. MacDougall, the board is comprised of six directors, five of whom are independent of Helix.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
Helix BioPharma Corp.
Tel: 905 841-2300